Paris-based Astraveus formed a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) to evaluate The Lakhesys Benchtop Cell Factory
for the manufacturing of CAR-T therapies.
NecstGen will use Astraveus’ Lakhesys product at its facility in Leiden to determine its potential to reduce costs and increase efficiency in CAR-T manufacturing compared to current industry benchmarks. Additionally, NecstGen will produce Lentiviral vectors for Astraveus’ internal research and development needs.
Officials at Astraveus said its scientists recently demonstrated the potential of the Lakhesys with the first, end-to-end production of CAR-T cells within a microfluidic benchtop system. The company is now starting external testing of its new manufacturing platform. Astraveus’ technology and its microfluidic approach possess the ability to simultaneously decrease manufacturing costs as well as increase process efficiency and throughput, according to Jérémie Laurent, PhD, CEO of Astraveus.
“This partnership, with a leading European center of excellence for cell and gene therapy, enables Astraveus to carry out external system demonstrations of our disruptive technology in a highly collaborative and transparent manner,” said Laurent.
“Astraveus’ novel approach to the manufacturing of CAR-T cells represents a breakthrough technology with the ability to transform the industry by enabling the faster and cheaper development of these cutting-edge treatments,” added Paul Bilars, CEO of NecstGen.
Located in a purpose-built GMP facility at the Leiden Bio Science Park, NecstGen, a non-profit CDMO, supports academic, small, and large industrial therapy developers to translate research and early-stage clinical programs into patient treatments.
The post Astraveus Enters CAR-T Therapy Manufacturing Partnership with NecstGen appeared first on GEN - Genetic Engineering and Biotechnology News.
NecstGen will use Astraveus’ Lakhesys product at its facility in Leiden to determine its potential to reduce costs and increase efficiency in CAR-T manufacturing compared to current industry benchmarks. Additionally, NecstGen will produce Lentiviral vectors for Astraveus’ internal research and development needs.
Officials at Astraveus said its scientists recently demonstrated the potential of the Lakhesys with the first, end-to-end production of CAR-T cells within a microfluidic benchtop system. The company is now starting external testing of its new manufacturing platform. Astraveus’ technology and its microfluidic approach possess the ability to simultaneously decrease manufacturing costs as well as increase process efficiency and throughput, according to Jérémie Laurent, PhD, CEO of Astraveus.
“This partnership, with a leading European center of excellence for cell and gene therapy, enables Astraveus to carry out external system demonstrations of our disruptive technology in a highly collaborative and transparent manner,” said Laurent.
“Astraveus’ novel approach to the manufacturing of CAR-T cells represents a breakthrough technology with the ability to transform the industry by enabling the faster and cheaper development of these cutting-edge treatments,” added Paul Bilars, CEO of NecstGen.
Located in a purpose-built GMP facility at the Leiden Bio Science Park, NecstGen, a non-profit CDMO, supports academic, small, and large industrial therapy developers to translate research and early-stage clinical programs into patient treatments.
The post Astraveus Enters CAR-T Therapy Manufacturing Partnership with NecstGen appeared first on GEN - Genetic Engineering and Biotechnology News.